MONOVISC

CROSS-LINKED SODIUM HYALURONATE

MONOVISC is a highly concentrated cross-linked hyaluronic acid viscosupplement used to relieve pain caused by osteoarthritis.
MONOVISC is produced from ultra-pure sodium hyaluronate, a high molecular weight produced by bacterial fermentation.

#1 VISCOSUPPLEMENT in the USA.

MONOVISC is FDA approved, MONOVISC & ORTHOVISC are the most prescribed viscosupplements in the USA.

Why MONOVISC?

  • Convenient single injection treatment
  • Highest dose of HA (88mg)
  • FDA approved
  • No animal origin
  • Provides strong and proven long-lasting pain relief of up to 26 weeks[7,8]
  • More than a million apps worldwide
  • Safely used for more than 10 years

CLINICALLY PROVEN PAIN RELIEF IN 6 MONTHS

  • MONOVISC 65% improvement in WOMAC pain score at 26 weeks, compared to baseline (p = 0.0352)[10]
  • MONOVISC 85% improvement in OMERACT-OARSI Index over 26 weeks[6]
  • MONOVISC clinically significant reduction in osteoarthritis knee pain within 2 weeks of injection[11]

Link: https://www.anikatherapeutics.com/products/pain_management/monovisc/

[6] CINGAL 13- 01, a randomized, double-blind, placebo-controlled, active comparator Phase 3 study.
[7] Clinical Ecacy and Safety of MONOVISC™: A lightly cross-linked highly concentrated hyaluronan specially formulated for single injection in osteoarthritis. White Paper Study conducted by Michael J. Daley, PhD. 2013
[8] Post-Approval Study of MONOVISC®, A Symptomatic Treatment of Osteoarthritis, White Paper, 2012.
[9] Information from package inserts.
[10] Hangody L, Szody R, Lukasik P, et al. Cartilage 2017 May; doi:10.1177/1947603517703732.
[11] Petterson SC, Plancher KD. Knee Surg Sports Traumatol Arthrosc (2018). https://doi.org/10.1007/s00167-018-5114-0

RELITED PRODUCTS